Effects of @entity3724 on plasma lipoproteins in XXXX and @entity5703 .

@entity407 @entity5703 @entity3724 @entity1 @entity753 @entity1007 @entity1910 @entity6308 @entity412 @entity731 @entity65 @entity165
To investigate the lipoprotein effect of @entity3724 in @entity1007 or @entity5703 (types II A and II B @entity407 , respectively), 240 @entity1 were recruited and 227 randomized to a double-blind randomized trial lasting 24 weeks and 192 @entity1 continued to participate in an open-label phase for another 24 weeks. A 100-mg dose of @entity3724 or a matching placebo was given three times daily. @entity3724 side effects in excess of placebo affected 6 percent of @entity3724 users and were confined almost entirely to @entity1910 . In 180 @entity753 @entity1 randomly assigned to receive @entity3724 versus placebo, @entity412 and very low-density lipoprotein @entity165 levels decreased 38 percent, total @entity165 levels decreased 17.5 percent, and low-density lipoprotein @entity165 levels decreased 20.3 percent with @entity3724 treatment. High-density lipoprotein @entity165 levels increased 11.1 percent with a decrease in the low-density lipoprotein @entity165 : high-density lipoprotein @entity165 ratio of 27 percent. All differences were statistically significant (p less than 0.01). In combined hyperlipidemic (type II B) @entity1 , @entity412 levels decreased by 45 percent, very low-density lipoprotein @entity165 levels decreased 52.7 percent, total @entity165 levels decreased 16 percent, low-density lipoprotein @entity165 levels decreased 6 percent, and high-density lipoprotein levels increased 15.3 percent for a low-density lipoprotein @entity165 : high-density lipoprotein @entity165 ratio decrease of 13 percent. All differences were again statistically significant (p less than 0.01). In both groups of @entity1 , the onset of the drug effect was generally rapid, with maximal total and low-density lipoprotein @entity165 level lowering achieved within four weeks in @entity753 @entity1 and maximal @entity412 and @entity165 level lowering in @entity6308 @entity1 achieved in two weeks. Maximum high-density lipoprotein increases occurred after four weeks in type II A @entity1 and 12 to 16 weeks in type II B @entity1 . @entity3724 is a well-tolerated drug in the fibric acid series and has putatively beneficial effects on @entity412 , very low-density lipoprotein, low-density lipoprotein, and high-density lipoprotein @entity165 concentrations in both type II A and type II B hyperlipidemic @entity1 . If the lipid hypothesis of @entity731 applies to the lipoprotein changes induced by @entity3724 , reductions in @entity65 risk in both type II A and II B hyperlipidemic @entity1 should result from @entity3724 treatment.
